MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to assess the safety and efficacy of MDMA-Assisted Therapy on Health Care Workers suffering from symptoms of Post-Traumatic Stress due to their work on the frontline of the COVID Pandemic.

Clinical Trial Description

After being informed about the study and potential risks, screening participants who sign the Informed Consent form will go through multiple screening visits (onsite and remote) designed to assess psychiatric and medical appropriateness for the study treatment. Tapering of certain medications are required. The screening period takes between 3 to 7 weeks and includes two preparatory sessions (90 minutes each) with the participant's assigned therapy team. Once a screening participant is deemed eligible for the study, baseline measures of symptomatology are obtained and a third preparatory session is conducted. The participant then enters into the Active Treatment Period which begins with the first of two all-day dosing sessions followed by three 90-minute integration (non-drug) sessions scheduled approximately a week and a half apart. Approximately 3 to 5 weeks after the first dosing session, a second all-day dosing session takes place, followed again by three 90-minute integration (non-drug) sessions scheduled about a week and a half apart. The total time to complete the Active Treatment Phase is between 4 and 9 weeks. Two to four weeks after the Active Treatment Phase, participants will meet with therapy team for a Treatment Termination Visit during which participants will complete primary outcome measures. Six months later, participants will be contacted and asked to repeat study measures to assess durability of effects. From Screening to Treatment Termination, participation in the study takes between 9 and 27 weeks. Some non-drug sessions can be done remotely at the discretion of the therapy team. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05455996
Study type	Interventional
Source	Nautilus Sanctuary
Contact	Willa Hall, Ph.D.
Phone	9175091497
Email	willa@nautilussanctuary.org
Status	Not yet recruiting
Phase	Phase 2
Start date	October 2022
Completion date	April 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04317820` - Deep Brain Reorienting in Post-traumatic Stress Disorder	N/A
Completed	`NCT05112003` - Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot	N/A
Recruiting	`NCT04518267` - Anger and Psychotrauma: Data From Military and Civilians
Completed	`NCT02502604` - Cognitive Training Program for Individuals With Depression and Post-Traumatic Stress Disorder	N/A
Completed	`NCT02256566` - Cognitive Training for Mood and Anxiety Disorders	N/A
Terminated	`NCT02234687` - A mGlu2/3 Agonist in the Treatment of PTSD	Phase 1
Terminated	`NCT02520726` - PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims	Phase 4
Completed	`NCT01738308` - The Effects of Healing Touch on Post Operative Pediatric Patients	N/A
Completed	`NCT02213900` - Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy	Phase 4
Completed	`NCT01437891` - Sentra AM® and Sentra PM® for Post-traumatic Stress Disorder (PTSD) and Gulf War Fibromyalgia (GWF)	N/A
Completed	`NCT01517711` - Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD)	Phase 4
Completed	`NCT01998100` - Maximizing Treatment Outcome in Post-Traumatic Stress Disorder (PTSD)	Phase 3
Completed	`NCT01199107` - Maximizing Treatment Outcome and Examining Sleep in Post-traumatic Stress Disorder (PTSD)	Phase 3
Completed	`NCT01231711` - Improving Quality-of-life and Depressive Symptoms of Combat Veterans Via Internet-based Intervention	Phase 1
Completed	`NCT00680524` - Telephone-based Care for OEF/OIF Veterans With PTSD	N/A
Completed	`NCT00348036` - Group Intervention for Interpersonal Trauma	N/A
Completed	`NCT00838006` - Psychophysiologic Predictors of Post-deployment Mental Health Outcomes	N/A
Completed	`NCT00525226` - Evaluating the Effects of Stress in Pregnancy	N/A
Completed	`NCT00158262` - Effect of Propranolol on Preventing Posttraumatic Stress Disorder	Phase 4
Completed	`NCT00183690` - Prolonged Exposure Therapy Versus Active Psychotherapy in Treating Post-Traumatic Stress Disorder in Adolescents	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.